Syverson Strege & Co’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Syverson Strege & Co’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,215	Closed	-$73K	–	272
2020 Q4	$73K	Buy	+1,215	New	+$69.3K	0.07%	97

Other funds holding IHE

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Syverson Strege & Co's IHE Position: Q1 2021 in Review

Syverson Strege & Co sold out of iShares US Pharmaceuticals ETF (IHE) in Q1 2021, closing a stake of 1,215 shares — an estimated $73K sold.

Syverson Strege & Co first reported a position in IHE in Q4 2020 and held it in 1 quarter. The position peaked at $73K in Q4 2020. 101 funds tracked by Wall St. Rank hold IHE as of Q1 2021.

Syverson Strege & Co reported no remaining iShares US Pharmaceuticals ETF position as of Q1 2021 after selling out during the quarter.
Syverson Strege & Co sold 1,215 iShares US Pharmaceuticals ETF shares in Q1 2021, an estimated $73K.
Syverson Strege & Co first reported a position in iShares US Pharmaceuticals ETF in Q4 2020 and held it in 1 quarter.
Syverson Strege & Co's iShares US Pharmaceuticals ETF position peaked at $73K in Q4 2020.
101 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q1 2021.

Based on Syverson Strege & Co's 13F filing for Q1 2021, filed 7 May 2021.